推荐产品
化驗
99.90%
形狀
wire
製造商／商標名
Goodfellow 027-639-63
電阻係數
57 μΩ-cm, 20°C
長度 × 直徑
0.1 m × 0.5 mm
bp
3338 °C (lit.)
mp
1522 °C (lit.)
密度
4.469 g/mL at 25 °C (lit.)
SMILES 字串
[Y]
InChI
1S/Y
InChI 密鑰
VWQVUPCCIRVNHF-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
一般說明
For updated SDS information please visit www.goodfellow.com.
法律資訊
Product of Goodfellow
儲存類別代碼
13 - Non Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Dan Li et al.
Journal of nanoscience and nanotechnology, 14(6), 4207-4213 (2014-04-18)
YF3:Er3+ hollow nanofibers were successfully fabricated via fluorination of the relevant Y2O3:Er3+ hollow nanofibers which were obtained by calcining the electrospun PVP/[Y(NO3)3 + Er(NO3)3] composite nanofibers. The morphology and properties of the products were investigated in detail by X-ray diffraction
Hojjat Ahmadzadehfar et al.
Seminars in nuclear medicine, 40(2), 105-121 (2010-02-02)
Radioembolization (RE), also termed selective internal radiation therapy (SIRT), has been gradually introduced to the clinical arsenal of cytoreductive modalities in recent years. There is growing evidence for efficiency in liver tumors of various entities, with the most prominent ones
Yukiko Ishihara et al.
Analytical sciences : the international journal of the Japan Society for Analytical Chemistry, 31(8), 781-785 (2015-08-11)
With a view to enhance the sensitivity of analytical instruments used in the measurement of trace elements contained in a single cell, we have now equipped the previously reported micro-droplet injection system (M-DIS) with a desolvation system. This modified M-DIS
G Scholz et al.
Dalton transactions (Cambridge, England : 2003), 44(30), 13522-13529 (2015-07-03)
Nanoscopic yttrium acetate fluorides Y(CH(3)COO)(3-z)F(z) and yttrium oxide fluorides YO(3-z)/(2)F(z )were prepared with tunable Y/F molar ratios via the fluorolytic sol-gel route. All samples were characterized by X-ray diffraction, elemental analysis and thermal analysis. In addition, local structures of all
Aki Aoyama et al.
Molecular cancer therapeutics, 13(12), 2978-2990 (2014-10-15)
Tivantinib (ARQ197) was first reported as a highly selective inhibitor of c-MET and is currently being investigated in a phase III clinical trial. However, as recently reported by us and another group, tivantinib showed cytotoxic activity independent of cellular c-MET
Active Filters
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持
